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Background: Heart failure (HF) patients have a high risk of death, and implantable cardioverter defibrillators (ICDs)
are effective in preventing sudden cardiac death (SCD). However, a certain percentage of patients may not be
immediate candidates for ICDs, particularly those having a short duration of risk or an uncertain amount of risk. This
includes the newly diagnosed patients, as well as those on the cardiac transplant list or NYHA class IV heart failure
patients who do not already have an ICD. In these patients, a wearable cardioverter defibrillator (WCD) may be
used until long term risk of SCD is defined. The purpose of this study was to determine the incidence of SCD in
this population, and the efficacy of early defibrillation by a WCD.
Methods: Ten enrolling centers identified 89 eligible HF patients who were either listed for cardiac transplantation,
diagnosed with dilated cardiomyopathy, or receiving inotropic medications. Data collected included medical
history, device records, and outcomes (including 90 day mortality).
Results: Out of 89 patients, final data on 82 patients has been collected. Patients wore the device for 75±58 days.
Mean age was 56.8±13.2, and 72% were male. Most patients (98.8%) were diagnosed with dilated cardiomyopathy
with a low ejection fraction (<40%) and twelve were listed for cardiac transplantation. Four patients were on
inotropes. There were no sudden cardiac arrests or deaths during the study. Interestingly, 41.5% of patients were
much improved after WCD use, while 34.1% went on to receive an ICD.
Conclusions: In conclusion, the WCD monitored HF patients until further assessment of risk. The leading reasons
for end of WCD use were improvement in left ventricular ejection fraction (LVEF) or ICD implantation if there was
no significant improvement in LVEF.
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Sudden cardiac death (SCD) is believed to account for
40 to 70% of the mortality associated with conges-
tive heart failure (HF), with progressive pump failure
causing the majority of the remaining fatalities [1,2].
Current figures estimate that 20% of HF patients
will die within one year of diagnosis [3], which repre-
sents an improvement over prior decades [4]. Thus,
the sudden death rate in the first year of diagnosis is
about 10%, mostly resulting from terminal ventricular
arrhythmias. Further complicating the situation, some* Correspondence: akao@cc-pc.com
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reproduction in any medium, provided the ormedications used in the treatment of HF (ie, inotropes
and diuretics) can also contribute to ventricular tachy-
cardia (VT) in patients [5]. Implantable cardioverter-
defibrillators (ICDs) are effective in preventing SCD in
HF due to ischemic and non-ischemic cardiomyopathy
when cardiac function, as measured by ejection fraction
(EF), is ≤ 35% [6-9]. HF patients on heart transplant
lists have also been shown to benefit from ICDs [10-12].
However, ICDs may not be the most cost-effective [13],
or the best method of reducing the incidence of sudden
death in all HF patients, particularly in patients having
a short (or uncertain) duration of risk or those with
drug refractory NYHA class IV HF [14]. According to
AHA/ACC/HRS guidelines for ICDs, newly diagnosed
nonischemic dilated cardiomyopathy (NIDCM) patients. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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months, before implantation [15]. Conversely, wearable
cardioverter defibrillators (WCD) such as the LifeVestW
device (manufacturer: ZOLL, Pittsburgh, PA) can be
used immediately to protect against SCD until long-
term risk of sudden death is established or cardiac func-
tion improves.
The WCD (LifeVestW, ZOLL, Pittsburgh, PA) was
FDA-approved in 2001 as an outpatient device after a
clinical trial involving 285 out-of-hospital patients [16].
WCDs are intended for use in adult patients that have
an increased risk of SCD if an ICD is not warranted.
Since approval, more than 60,000 patients have used the
LifeVestW on an outpatient basis for a wide variety of
conditions. Like ICDs, WCDs are designed to detect
and treat ventricular tachyarrhythmias without the need
for bystander intervention. Unlike ICDs, they are com-
pletely external to the body and do not require surgical
intervention. Thus, they are ideal for shorter-term
applications where the risk of SCA is changing or uncer-
tain. WCD use in the HF population is limited [16,17].
In order to gain further clinical experience with WCD
use in this population, ZOLL sponsored the WIF (Wear-
able defibrillator use In heart Failure) registry. The pri-
mary purpose of the WIF registry was to determine the
incidence of SCA in this population, the cause of SCA
(bradyarrhythmias or tachyarrhythmias), and the effi-
cacy of early defibrillation given by the WCD. Three
patient groups were followed; patients listed for heart
transplantation, patients with dilated cardiomyopathy




The WIF study was designed to collect SCA events,
WCD defibrillation efficacy, and WCD usage data in
HF patients. The WCD usage criteria was defined as
met if median daily use was at least 85% of the day in
those patients that wore the device for at least 7 days.
WCD prescription length was not prespecified, but
was anticipated to be 3 months. The WCD (LifeVestW,
ZOLL, Pittsburgh, PA) is FDA approved for use in this
population, and is reimbursed by Medicare and other
insurers. The study was sponsored by the manufacturer
(ZOLL, Pittsburgh, PA).Sites
Ten centers with WCD prescribing physicians were
selected for the study based upon expressed interest. All
sites were in the US and included both academic and
community centers.Study population
Patients were enrolled from July 1, 2007 through
February 1, 2010. For the purposes of this registry,
HF patients were screened if they were: 1) listed (or
being considered) for heart transplantation, and/or, 2)
they had DCM (with VT or EF ≤ 40%), and/or, 3) the
patient was receiving inotropes. HF patients were
excluded from the study if they had an active ICD or if
they were impaired such that they could not use the
device. Age, pregnancy, and time since HF diagnosis
were not exclusion criteria. The device’s default VT and
VF detection rates were set at 150 and 200 beats per
minute, respectively, and the default shock energy was
set at 150 joules. However, physicians had the ability to
change these settings. A sample size of 500 was origin-
ally specified in order to capture multiple SCA events
based on an estimated event rate of one or two percent
over the three month study period. However, due to
lower than expected site participation the registry was
terminated after three years.
Data collection
The protocol, informed consent document, and relevant
supporting information was submitted and approved for
each study site by their local institutional review board,
for Saint Luke’s Hospital of Kansas City, Albert Einstein
Health Care Network, and The University of Iowa, or a
national institutional review board (Schulman Associates)
before the study was initiated in accordance with ethical
principles that have their origin in the Declaration of
Helsinki and consistent with Good Clinical Practice and
applicable regulatory requirements. Patient demographics,
limited medical history, medications, laboratory results,
and cardiac testing were collected upon entry. WCD
device records were interrogated to determine compliance
with use, defibrillation events, and arrhythmia detec-
tion. WCD ECG recordings, whether patient initiated or
automatic, were also collected. Reasons for WCD device
removal, cardiac events during the study, medications,
and cardiac testing data were collected at the end of
WCD use. Patient survival during WCD use was deter-
mined three months after the patient began participation.
The social security death index (SSDI) was used to deter-
mine all cause-mortality after WCD use. The duration
of follow-up was computed from the time of WCD start
until death for those who died, and to the final date
of data collection (June 9, 2010) for those who were
still alive.
Statistical analysis
Descriptive statistics were utilized to describe this popu-
lation based on data collected at the time of referral for
WCD therapy or after therapy. All values are reported
as means ± standard deviations. Student’s t test
Table 1 Baseline characteristics
Baseline characteristics Total (n=82)
Sex: Males (%) 59 (72%)
Age: Mean (SD) 61.0 (11.1)
Range 37-83
Baseline EF (SD) 23.9% (9.4%)
Range 7.5%-65%
Baseline NYHA class (%) n=74
Class I 11 (14.9%)
Class II 20 (27.0%)
Class III 40 (54.1%)
Class IV 3 (4.1%)
Prior MI (n=78) 17 (21.8%)
Prior PCI (n=80) 10 (12.5%)
Prior CABG (n=81) 17 (21.0%)
Prior sustained VT (n=82) 4 (4.9%)
Prior VF (n=79) 1 (1.3%)
HTN (n=81) 55 (67.9%)
Diabetes (n=81) 36 (44.4%)







Atrial Fibrillation 8 (9.9%)
Bradycardia 3 (3.7%)
Sinus rhythm with 1st deg AV block 2 (2.5%)
Left bundle branch block 3 (3.7%)
Right bundle branch block 2 (2.5%)
Sinus tachycardia 12 (14.8%)
Multiple PVCs 4 (4.9%)
Device History
Active pacemaker 2 (2.4%)
Past/inactive pacemaker 2 (2.4%)
Prior/inactive ICD 4 (4.9%)
Medications
Beta Blockers 78 (95.1%)
ACE Inhibitors 63 (76.8%)
Angiotensin II Receptor Blockers 16 (19.5%)
Anti-arrhythmics 7 (8.5%)
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categorical data, was used where a p value of 0.05 was
considered statistically significant. The Pearson’s product–
moment correlation coefficient was calculated using the
free online academic software at www.wessa.net to test
whether a correlation existed between factors impacting
WCD use.
Results
The WIF registry began enrolling patients in mid July
2007. At the conclusion of the study in May 2010, 89
patients had been enrolled from ten centers. This report is
based on the analysis of data from 82 patients who com-
pleted the study. Of the seven who did not complete the
study, 4 were lost to study follow-up after completing
WCD use, and 3 dropped out after wearing the WCD for
a couple of hours. The cohort was predominantly male
(72%) with a mean age of 56.8 ± 13.2 years (range: 25–
82). Most patients were diagnosed with ischemic or
non-ischemic dilated cardiomyopathy (DCM) with a
low ejection fraction (EF) (98.8%), and twelve were
listed for cardiac transplantation. Four patients were on
inotropes, and three of these patients were also listed
for transplantation. Baseline characteristics are shown
in Table 1. The majority of patients had NYHA class II-
III HF, and only one patient started out with an EF
>45% (transplant rejection with VT). The etiology of the
cardiomyopathy was idiopathic in 39% of patients,
ischemic in 36% of patients, and a variety of other non-
ischemic causes (Table 2). Co-morbidities included
hypertension (68%), diabetes (44%), smoking (56%), and
obesity (42%). Seventy-eight patients (95.1%) were on
beta-blockers, 63 (76.8%) on ACE inhibitors, 16 (19.5%)
on angiotensin II receptor blockers, and seven (8.5%) on
amiodarone. Only 5 (6.1%) patients had a prior history
of sustained ventricular dysrhythmias. Time since first
HF diagnosis was not collected.
Compliance with the WCD
The average period of WCD usage for all patients was
79.5±57.8 days (median: 79, range: 1–277). Two patients
were still wearing the device at the end of the study.
Compliance with wearing the WCD was then calculated
based on patients who wore the device for 7 days or greater
(n=75). The average daily device use was 19.5±4.6 hr/day
(median: 21.8; range: 3.7-23.7) over an average of 75.1±57.7
days (median: 64; range: 7–277). Average daily use was
significantly correlated to total days worn (r=0.300, p<0.01).
Outcomes
There were no SCA events or deaths during the study,
and 90- day survival after WCD fitting was 100%.
There were also no adverse events or inappropriate
shocks by the WCD. Two patients (2.7%) complainedof palpitations, and five patients (6.8%) complained of
lightheadedness or fainting during WCD use, with no
sustained ventricular arrhythmias or asystoles detected
by the WCD. Three patients had a CABG procedure
during WCD use but none had percutaneous coronary




Alcohol/recreational drugs 6 (7.5%)




Allograft Rejection 1 (1.3%)
Pharmacological 1 (1.3%)
Peripartum 1 (1.3%)
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was similar to baseline, with 95.7% on beta-blockers,
72.5% on ACE inhibitors, 20.3% on angiotensin II receptor
blockers, and 15.9% on amiodarone. Four patients under-
went an electrophysiology (EP) study after discharge. One
patient had an inconclusive EP result, one had a positive
result, and two had a negative test. The first two patients
then underwent ICD implantation.
At the time of WCD discontinuation, 34 (41.5%)
patients were considered much improved and no longer
needed the WCD due to either an improved EF (defined
as EF ≥ 35% at the time use ended) (31 out of 34), acute
allograft rejection resolved (1 of 34), feeling better (1 of
34), and one unknown reason. Twenty-eight (34.1%)
went on to receive an ICD implant. Six (7.3%) refused to
wear the device due to discomfort or other reasons,
seven (8.5%) patients had an unknown/other reason for
removing their WCD. Two (2.4%) transitioned to “do
not resuscitate” status, one (1.2%) received a heart
transplant, one (1.2%) had aortic/mitral/tricuspid valve
repair, one (1.2%) had frequent inappropriate detections,
and two (2.4%) patients were still using the WCD at the
close of the study (Figure 1). Although a greaterFigure 1 WCD end of use reasons. The reported reasons for ending WCDproportion of presumed non-ischemic patients ended
WCD use due to improvement as compared to ischemic
patients (50% vs. 34%), it was not statistically different
(p=0.267). Likewise, 32% of non-ischemic patients
received ICD after WCD use vs. 45% of ischemic
patients.
Improved LVEF during WCD use
The average final EF for all patients was 37.2%±14.6%
(n=70), with an average EF increase per patient of
13.5%±15.7%. This was a statistically significant im-
provement of EF since initial enrollment (p<0.001).
Fifteen patients had an EF >50% at the end of WCD
use. Baseline EF versus final EF per patient is shown in
Figure 2(a,b). Those patients with lower baseline EF
experienced the greatest improvement in EF (Figure 2b).
Only one patient with a high baseline EF was enrolled by
virtue of transplant rejection with VT. The average length
of prescription to ICD implant was 77±55 days (me-
dian:76), while the average length of time between pre-
scription to EF improvement was 82±58 days (median:85).
Figure 2c shows change in EF according to outcome
(improved, received ICD, or other). The average final EF
before ICD implant was 25.5%±9.5% (n=20). The final EF
of those patients who improved was 46.4%±9.8% com-
pared to a baseline of 25.5% ± 11.1% (n=33, p<0.0001).
Those experiencing EF improvement had an average
20.9% (or 1.8 fold) increase in their EF% from baseline.
There was no difference in baseline EF between those
who improved and those who did not. New York Heart
Association class also improved by 0.5±1.0 points since
initial enrollment (n=59, p<0.005). There were no signifi-
cant differences in beta-blocker, ACE-Inhibitor, or
angiotensin-II receptor blocker usage between those
patients who improved, and those who received an ICD
(data not shown). After WCD use, six patients (7.3%) died
from unknown causes 26, 56, 229, 254, 304, and 553 days
(average 288±176 days) after WCD discontinuation,use in all patients.
Figure 2 LVEF per patient over time. (A) LVEF (%) per patient at WCD initiation to WCD end. Data is shown for 70 patients who had both a
baseline and final EF measurement. (B) LVEF improvement grouped by starting LVEF (n=70). * denotes significance of p<0.001 as compared to
respective baseline EF. (C) Outcomes as related to initial and final LVEF. Average baseline and final LVEF (± SD) measurements are shown for all
patients having both a baseline and final EF recorded (n=70), patients who improved during WCD use (n=33), patients who received an ICD after
WCD use (n=20), and all remaining patients who ended use for other reasons (n=17). All groups, except those receiving ICDs, significantly
improved EF during the course of WCD use. Those patients who improved had the highest overall final EF. * denotes significance of p<0.005 as
compared to respective baseline EF. ** denotes significance of p<0.005 as compared to other final EF groups.
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who died 26 days after WCD use received an ICD
(EF=27.5%). The patients who died at 56 and 229 days
post- WCD use had an EF improvement (EF= 43% and
50%, respectively at the time of WCD end of use). The
patient who died 304 days after WCD use had stopped the
WCD due to discomfort. The patient who died 553 days
after WCD ended use was due to a lack of improvement
(EF=31%) and switch to a “do not resuscitate” status.
Patients on transplant list and inotropes
Twelve patients on the heart transplant list completed the
study. Four patients were able to remove the WCD after
their condition improved, four received ICDs, one had
aortic/mitral/tricuspid valve repair, one received a heart
transplant, and two ended WCD use for an unknown rea-
sons. Ninety day survival was 100%, although one patient
died 56 days after WCD discontinuation for improved EF,
according to the social security death index. Of the four
patients on inotropes; two received ICDs, one received a
heart transplant, and one had an improvement in EF but
died 56 days after WCD discontinuation (same patient as
above).Discussion
The intent of the WIF registry was to observe the use of
the WCD in a population of HF patients over a 90 day
period. The enrolled group represented a mix of dilated
cardiomyopathy patients (Tables 1 and 2), with the major-
ity of patients having an idiopathic (39%) or ischemic
(36%) etiology of HF. Twelve patients (14.6%) were listed
for cardiac transplantation, and four (4.9%) were on ino-
tropes. As one may expect from the small sample size that
resulted from lower than anticipated enrollment, there
were no SCA events in the 82 patients who completed the
study. Current WCD event statistics suggest an event rate
for new cardiomyopathy patients wearing the WCD to be
approximately 0.00013 VT/VF events per patient per day
[18]. Therefore, the chance of not having an event was
approximately 42%. Regardless, the WCD bridged the
DCM patients until long-term therapy decisions could be
made. There were also no adverse events or unnecessary
shocks by the WCD during the study. Daily compliance
with the WCD was a median of 21.8 hrs, which met our
goal of at least 85% median daily wear time. This compli-
ance is very similar to that of the current general commer-
cial population (median=21.7 hr/day) [18]. Seventy
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the day. Although assessing and comparing compliance is
difficult, compliance with the WCD is similar to compli-
ance with medications in HF populations [19].
Interestingly, 34 (41.5%) patients were considered
much improved at the end of the study and no longer
needed the WCD, mostly due to an improved EF (EF ≥
35%). This may have been due to the high rate of beta-
blocker use, or possibly because some patients had
reversible causes of disease. However, 33% of the 12
transplant-listed patients also showed improvement. To
our knowledge, few recent peer-reviewed studies have
analyzed improvement in ventricular function 60–90
days post-diagnosis or acute decompensation of DCM
[20,21]. The IMAC trial, which studied intravenous
immune globulin in recent onset DCM, also saw mean
LVEF increase significantly in patients from 25% to 41%
over a 6 month period regardless of treatment [22]. It
should also be emphasized that improvement in LV
function should not be taken as a “cure” and medica-
tions should be continued or monitored closely, as
relapses may occur [21]. Although we do not know the
cause of death, two patients who were discontinued
from the WCD due to EF improvement (EF=43% and
50%) died (56 and 229 days) after removing the WCD.
There was an overall 7.3% mortality rate over 288±176
days after being fit with the WCD. Unfortunately, this
time period was beyond the scope of the study and the
reasons for death are unknown. The mortality rate is
similar to that seen in the SCD-HeFT and DEFINITE
(non-ischemic) trials [7,9].
The benefits of prophylactic ICD implantation
remains contentious in DCM patients [14]. Although
ICDs have been shown to be beneficial in this group of
patients [7,8], it is not without risk, and the event rate
remains low (especially for those without prior MI) [23].
For this reason, risk stratification of these patients
remains extremely important. A recent study showed a
yearly increase in out-of-hospital mortality rates in
Medicare HF patients, possibly due to shortened hos-
pital stays [24]. It may be beneficial to the patient (and
society) to give the patient enough time to potentially
stabilize on medication and recover LV function, while
still keeping them protected and out of the hospital. It
may also be beneficial to avoid ICD placement in the
transplant-listed patient, if their wait is not expected to
be extremely long. These goals can be accomplished
with the WCD.
Study limitations
There were several limitations to this study. First, due to
the smaller than expected enrollment, the study did not
meet its primary objective of collecting SCA incidence
data. Also, 8.5% of those who were initially enrolled werelost to study follow-up. Second, factors affecting EF
improvement could not be analyzed fully due to the het-
erogeneic etiologies and unknown duration of disease.
Finally, the mortality rate in our study was determined
using the Social Security Death Index and may not have
captured all deaths in our population, leading to errone-
ous conclusions based on this data
Conclusions
In conclusion, the WCD monitored HF patients until
further assessment of risk. The leading reasons for end
of WCD use were improvement in left ventricular ejec-
tion fraction (LVEF) or ICD implantation if there was
no significant improvement in LVSF. Due to the smaller
than anticipated sample size, there were no SCD events
in the 82 patients who completed the study (≤90 days).
The overall 7.3% mortality rate over 288±176 days after
being fit with the WCD is similar to that seen in other
trials.
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